Pidotimod is a synthetic dipeptide molecule with immunomodulatory properties, primarily used as an immunostimulant. It acts on both innate and adaptive immunity, enhancing the body's defense mechanisms against recurrent respiratory and urinary tract infections. In the Indian context, it is widely prescribed for prophylaxis and treatment of recurrent infections in both adults and children, particularly in the changing seasons.
Adult: 800 mg twice daily for the first 14 days (loading phase), followed by 800 mg once daily for the next 60 days (maintenance phase). For acute episodes: 800 mg twice daily for 14 days alongside primary therapy.
Note: Administer orally, preferably on an empty stomach (at least 1 hour before or 2 hours after meals) for optimal absorption. The tablet can be taken with a glass of water. Do not crush or chew unless specified by the manufacturer (some brands are film-coated).
Pidotimod modulates the immune response by stimulating both cellular and humoral immunity. It promotes the maturation and differentiation of T-lymphocytes and enhances the phagocytic activity and chemotaxis of neutrophils and macrophages. It also increases the production of cytokines (e.g., IL-2, IFN-γ) and modulates antibody production.
Pregnancy: Category B2 (Australian categorization). Animal studies show no direct harm, but human data is insufficient. Use only if clearly needed and potential benefit justifies potential risk.
Driving: Pidotimod has no or negligible influence on the ability to drive and use machines. Dizziness, though rare, should be considered.
| Immunosuppressants (e.g., Cyclosporine, Tacrolimus, Corticosteroids) | Theoretical antagonism of Pidotimod's immunostimulant effect. | Moderate |
| Live Attenuated Vaccines | Theoretical risk of increased vaccine-related adverse events due to immune stimulation. A gap is advised. | Moderate |
| Other Immunomodulators | Additive or unpredictable immune effects. | Moderate |
Same composition (Pidotimod (800mg)), different brands: